相关实验视频

Updated: Jul 14, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

设计一种生物相容的奇托桑/MOF气凝,用于治疗肝功能衰竭的高白血症

Zhiwen Hu¹, Fangjiu He², Anxiong Liu¹

¹Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Clinical Research Center for Natural Polymer Biological Liver, Hubei Engineering Center of Natural Polymer-based Medical Materials, Wuhan 430071, China. yqf_china@163.com.

Journal of materials chemistry. B

|August 14, 2025

概括

研究人员开发了一种新的基托基气凝,用于治疗肝功能衰竭. 这种创新材料有效地去除胆红素并对抗感染,为患者护理提供了有前途的进步.

科学领域:

生物材料科学生物材料科学
肝病学肝病学是一种肝病学.
医学化学医学化学

背景情况:

肝衰竭每年导致数百万人的死亡,通常是由于高白血和感染.
目前治疗高白血症的方法缺乏选择性和生物安全性.
对于治疗肝功能衰竭的先进吸附剂有着极大的需求.

研究的目的:

开发一种基于素的HKUST-1气凝 (HC) 用于治疗肝功能衰竭.
为了评估气凝的胆红素吸附,生物安全和抗菌性质.
评估HC空气凝在超白血病动物模型中的疗效.

主要方法:

制造一种基于酸盐的HKUST-1气凝 (HC).
在体外评估胆红素吸附,生物安全和抗菌活性对黄金葡萄球菌和大肠杆菌.
在活体中评估高白血病动物模型中的胆红素清除.

主要成果:

在实验室中,HC气凝表现出高胆红素吸附能力.
该材料显示出显著的生物安全性和抗凝固特性.
在体内,HC气凝显示出抗菌活性和42.4%的胆红素清除.

结论:

HKUST-1/chitosan气凝是肝功能衰竭治疗的有希望的候选者.
气凝有效地将胆红素吸附与感染控制相结合.
这种生物材料为治疗肝衰竭并发症提供了潜在的解决方案.

更多相关视频

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

相关概念视频

Jaundice

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...